Abstract
Contrast-enhanced CT of chest and abdomen is the first-line procedure for staging of esophageal cancer. As CT is affected by a low accuracy in reliably detecting lymph node metastases, 18F-FDG PET/CT has a relevant additional contribution in this setting, although it cannot operate in distinguishing different T stages. Having been reported false-positive results in inflammatory/infective lesions, false-negative results, also at the level of lymph node metastases, may be related not only to little masses, but also to lesions showing a low FDG’s uptake [1]. PET/CT plays an important implemental role in defining N stage, especially when analyzed together with endoscopic ultrasounds (EUS). Furthermore, also because of the complementary contribution of CT, 18F-FDG PET/CT is the best predictor of M stage, involving lungs and liver and, more rarely, pleura, muscles, and skeleton [2, 3]. For all the reasons above, 18F-FDG PET/CT may change the management in up of 38% of patients diagnosed with esophageal cancer [4], having the capability to upstage the disease in approximately 20% of the subjects with respect to CT/EUS, taken alone [2, 3]. Therefore, PET/CT may be considered mandatory in precluding highly destroying and expensive curative surgery, mainly in patients with a high probability of distant metastases, although negative at CT/EUS. From recent studies, the association of PET and EUS is emerging as more cost effective with respect to CT and EUS to decide the therapeutic strategy after diagnosis [5]. More recently, a greater interest is growing on FDG’s capability to allow a “textural feature analysis,” based on the evaluation of intra-tumoral uptake’s heterogeneity. This information could define various patterns predicting a diverse response to chemoradiotherapy [6]. Interesting results, mainly in the evaluation of T and locoregional disease, could also be achieved by PET/MRI; unfortunately, this new tool is negatively affected by high costs and scarce diffusion, creating difficulties in reaching a cost-effectiveness justifying its use in the clinical practice [7].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Germany, part of Springer Nature
About this chapter
Cite this chapter
Fanti, S., Farsad, M., Mansi, L., Castellucci, P. (2018). Malignancies of the Upper Gastrointestinal Tract. In: Atlas of PET-CT. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57742-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-662-57742-4_9
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57740-0
Online ISBN: 978-3-662-57742-4
eBook Packages: MedicineMedicine (R0)